| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Fusion | 47 | 2023 | 153 | 11.920 |
Why?
|
| Postoperative Complications | 40 | 2022 | 631 | 7.430 |
Why?
|
| Spinal Diseases | 21 | 2020 | 43 | 6.730 |
Why?
|
| Elective Surgical Procedures | 25 | 2021 | 74 | 6.050 |
Why?
|
| Lumbar Vertebrae | 26 | 2023 | 129 | 4.010 |
Why?
|
| Patient Readmission | 16 | 2019 | 107 | 3.770 |
Why?
|
| Spine | 14 | 2022 | 62 | 3.410 |
Why?
|
| Retrospective Studies | 61 | 2023 | 2612 | 2.750 |
Why?
|
| Spinal Cord Neoplasms | 11 | 2021 | 40 | 2.500 |
Why?
|
| Spinal Curvatures | 5 | 2019 | 9 | 2.370 |
Why?
|
| Aged | 63 | 2021 | 5525 | 2.280 |
Why?
|
| Middle Aged | 67 | 2021 | 7310 | 2.160 |
Why?
|
| Length of Stay | 19 | 2021 | 240 | 2.150 |
Why?
|
| Male | 86 | 2021 | 13771 | 2.040 |
Why?
|
| Decompression, Surgical | 16 | 2018 | 78 | 1.960 |
Why?
|
| Female | 83 | 2021 | 15471 | 1.820 |
Why?
|
| Humans | 114 | 2023 | 28581 | 1.780 |
Why?
|
| Pain, Postoperative | 6 | 2022 | 62 | 1.750 |
Why?
|
| Neurosurgical Procedures | 17 | 2021 | 223 | 1.730 |
Why?
|
| Treatment Outcome | 35 | 2021 | 2402 | 1.720 |
Why?
|
| Cervical Vertebrae | 10 | 2021 | 118 | 1.690 |
Why?
|
| Patient Reported Outcome Measures | 7 | 2019 | 66 | 1.640 |
Why?
|
| Scoliosis | 9 | 2019 | 36 | 1.590 |
Why?
|
| Delirium | 5 | 2020 | 13 | 1.590 |
Why?
|
| Adult | 49 | 2021 | 7922 | 1.420 |
Why?
|
| Laminectomy | 11 | 2020 | 31 | 1.390 |
Why?
|
| Narcotics | 2 | 2019 | 11 | 1.230 |
Why?
|
| Spinal Cord Diseases | 4 | 2017 | 33 | 1.220 |
Why?
|
| Thoracic Vertebrae | 10 | 2018 | 70 | 1.150 |
Why?
|
| Fluoroscopy | 3 | 2023 | 36 | 1.120 |
Why?
|
| Kyphosis | 5 | 2021 | 19 | 1.120 |
Why?
|
| Mental Disorders | 2 | 2021 | 112 | 1.120 |
Why?
|
| Pedicle Screws | 4 | 2023 | 14 | 1.090 |
Why?
|
| Surgical Wound Infection | 7 | 2022 | 107 | 1.040 |
Why?
|
| Sacrum | 6 | 2021 | 25 | 1.030 |
Why?
|
| Diskectomy | 4 | 2021 | 23 | 1.010 |
Why?
|
| Reoperation | 8 | 2020 | 153 | 0.980 |
Why?
|
| Orthopedic Procedures | 5 | 2020 | 27 | 0.980 |
Why?
|
| Spinal Stenosis | 5 | 2017 | 15 | 0.960 |
Why?
|
| Young Adult | 19 | 2020 | 2804 | 0.960 |
Why?
|
| Pseudarthrosis | 4 | 2021 | 6 | 0.950 |
Why?
|
| Surgery, Computer-Assisted | 4 | 2023 | 33 | 0.940 |
Why?
|
| Radiography | 9 | 2020 | 203 | 0.920 |
Why?
|
| Minimally Invasive Surgical Procedures | 4 | 2018 | 77 | 0.910 |
Why?
|
| Aged, 80 and over | 21 | 2020 | 2045 | 0.900 |
Why?
|
| Mood Disorders | 2 | 2019 | 25 | 0.740 |
Why?
|
| Osteotomy | 2 | 2019 | 24 | 0.730 |
Why?
|
| Cohort Studies | 17 | 2020 | 893 | 0.720 |
Why?
|
| Adolescent | 17 | 2020 | 3165 | 0.710 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 42 | 0.710 |
Why?
|
| Community Mental Health Services | 1 | 2021 | 16 | 0.690 |
Why?
|
| Risk Factors | 16 | 2022 | 2111 | 0.690 |
Why?
|
| Depression | 3 | 2019 | 222 | 0.690 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2020 | 478 | 0.690 |
Why?
|
| Incidental Findings | 1 | 2020 | 13 | 0.680 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 117 | 0.680 |
Why?
|
| Astrocytoma | 4 | 2015 | 37 | 0.670 |
Why?
|
| Lumbosacral Region | 2 | 2017 | 22 | 0.660 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 118 | 0.640 |
Why?
|
| Monitoring, Intraoperative | 3 | 2017 | 30 | 0.640 |
Why?
|
| Pain | 3 | 2019 | 258 | 0.630 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 116 | 0.630 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 534 | 0.620 |
Why?
|
| Blood Transfusion | 1 | 2020 | 77 | 0.610 |
Why?
|
| Hemangioma, Capillary | 3 | 2013 | 4 | 0.610 |
Why?
|
| Biomarkers, Tumor | 3 | 2014 | 409 | 0.610 |
Why?
|
| Mobility Limitation | 1 | 2019 | 15 | 0.610 |
Why?
|
| Spinal Neoplasms | 5 | 2021 | 40 | 0.610 |
Why?
|
| Intraoperative Complications | 3 | 2017 | 47 | 0.600 |
Why?
|
| African Americans | 4 | 2018 | 352 | 0.600 |
Why?
|
| Age Factors | 8 | 2017 | 734 | 0.590 |
Why?
|
| Bone Malalignment | 1 | 2018 | 1 | 0.590 |
Why?
|
| Low Back Pain | 4 | 2016 | 29 | 0.580 |
Why?
|
| Epidural Abscess | 3 | 2019 | 3 | 0.580 |
Why?
|
| Prospective Studies | 12 | 2020 | 1272 | 0.570 |
Why?
|
| Operative Time | 5 | 2017 | 41 | 0.560 |
Why?
|
| Osteoporosis | 1 | 2018 | 63 | 0.550 |
Why?
|
| Anemia | 1 | 2018 | 43 | 0.550 |
Why?
|
| Radiographic Image Enhancement | 1 | 2017 | 28 | 0.550 |
Why?
|
| Time-to-Treatment | 2 | 2021 | 29 | 0.540 |
Why?
|
| Urinary Tract Infections | 2 | 2016 | 39 | 0.540 |
Why?
|
| Self Concept | 2 | 2018 | 53 | 0.530 |
Why?
|
| Robotic Surgical Procedures | 3 | 2023 | 51 | 0.530 |
Why?
|
| Radiation Exposure | 1 | 2017 | 17 | 0.520 |
Why?
|
| Vancomycin | 1 | 2017 | 58 | 0.520 |
Why?
|
| Depressive Disorder | 1 | 2017 | 56 | 0.520 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 38 | 0.520 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 47 | 0.520 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 19 | 0.510 |
Why?
|
| Obesity | 3 | 2019 | 675 | 0.500 |
Why?
|
| Time Factors | 11 | 2019 | 1600 | 0.500 |
Why?
|
| Nutritional Status | 1 | 2016 | 79 | 0.480 |
Why?
|
| Spinal Fractures | 4 | 2020 | 43 | 0.470 |
Why?
|
| Ependymoma | 1 | 2015 | 11 | 0.460 |
Why?
|
| Hemangioblastoma | 1 | 2015 | 12 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 337 | 0.450 |
Why?
|
| Child | 11 | 2020 | 2271 | 0.450 |
Why?
|
| Chordoma | 1 | 2014 | 9 | 0.430 |
Why?
|
| Comorbidity | 4 | 2019 | 259 | 0.420 |
Why?
|
| Follow-Up Studies | 11 | 2018 | 1026 | 0.420 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2020 | 834 | 0.410 |
Why?
|
| Brain Neoplasms | 5 | 2015 | 311 | 0.410 |
Why?
|
| Smoking | 1 | 2017 | 476 | 0.400 |
Why?
|
| Child, Preschool | 6 | 2015 | 1167 | 0.400 |
Why?
|
| Achondroplasia | 1 | 2012 | 2 | 0.380 |
Why?
|
| Pelvic Bones | 1 | 2012 | 15 | 0.380 |
Why?
|
| Patient Satisfaction | 3 | 2018 | 96 | 0.380 |
Why?
|
| Spinal Cord Injuries | 3 | 2021 | 62 | 0.360 |
Why?
|
| Sarcoma, Ewing | 1 | 2011 | 15 | 0.360 |
Why?
|
| Recovery of Function | 2 | 2013 | 122 | 0.350 |
Why?
|
| Oculomotor Nerve | 1 | 2010 | 3 | 0.340 |
Why?
|
| Endoderm | 1 | 2010 | 2 | 0.340 |
Why?
|
| Prevalence | 5 | 2019 | 510 | 0.340 |
Why?
|
| Central Nervous System Cysts | 1 | 2010 | 4 | 0.340 |
Why?
|
| Patient Transfer | 3 | 2021 | 43 | 0.330 |
Why?
|
| United States | 6 | 2022 | 2201 | 0.330 |
Why?
|
| Conservative Treatment | 2 | 2021 | 11 | 0.330 |
Why?
|
| Infant | 5 | 2015 | 1019 | 0.330 |
Why?
|
| Sternotomy | 1 | 2009 | 7 | 0.320 |
Why?
|
| Aging | 2 | 2016 | 979 | 0.320 |
Why?
|
| Patient Discharge | 4 | 2018 | 108 | 0.310 |
Why?
|
| Bullying | 2 | 2020 | 7 | 0.310 |
Why?
|
| Glioblastoma | 4 | 2015 | 109 | 0.310 |
Why?
|
| Melanocytes | 1 | 2009 | 13 | 0.310 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 302 | 0.300 |
Why?
|
| Erythrocyte Transfusion | 2 | 2020 | 15 | 0.300 |
Why?
|
| Orbital Neoplasms | 1 | 2009 | 11 | 0.300 |
Why?
|
| Logistic Models | 4 | 2017 | 409 | 0.300 |
Why?
|
| Intracranial Hypotension | 2 | 2020 | 6 | 0.290 |
Why?
|
| Pain Perception | 2 | 2019 | 17 | 0.290 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 480 | 0.280 |
Why?
|
| Preoperative Care | 3 | 2021 | 81 | 0.280 |
Why?
|
| Meningeal Neoplasms | 1 | 2009 | 73 | 0.280 |
Why?
|
| Meningioma | 1 | 2009 | 79 | 0.280 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 68 | 0.280 |
Why?
|
| Lordosis | 2 | 2021 | 6 | 0.280 |
Why?
|
| Fourth Ventricle | 2 | 2013 | 3 | 0.270 |
Why?
|
| Melanoma | 1 | 2009 | 140 | 0.270 |
Why?
|
| Surgical Wound Dehiscence | 2 | 2017 | 16 | 0.260 |
Why?
|
| Radiation Dosage | 2 | 2017 | 54 | 0.260 |
Why?
|
| Epidural Neoplasms | 1 | 2007 | 1 | 0.260 |
Why?
|
| Spina Bifida Occulta | 1 | 2007 | 1 | 0.260 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2007 | 1 | 0.260 |
Why?
|
| Activin Receptors, Type II | 1 | 2007 | 2 | 0.260 |
Why?
|
| Adrenocortical Adenoma | 1 | 2006 | 1 | 0.260 |
Why?
|
| Intraoperative Care | 2 | 2017 | 23 | 0.260 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2006 | 6 | 0.260 |
Why?
|
| Quality of Life | 3 | 2021 | 504 | 0.260 |
Why?
|
| Spinal Dysraphism | 1 | 2006 | 14 | 0.260 |
Why?
|
| Healthcare Disparities | 3 | 2018 | 93 | 0.250 |
Why?
|
| Walking | 2 | 2018 | 135 | 0.250 |
Why?
|
| Postoperative Period | 4 | 2018 | 68 | 0.240 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 147 | 0.230 |
Why?
|
| Spinal Cord | 3 | 2012 | 211 | 0.220 |
Why?
|
| Preoperative Period | 3 | 2019 | 15 | 0.220 |
Why?
|
| Pain Measurement | 4 | 2019 | 172 | 0.220 |
Why?
|
| Prognosis | 5 | 2017 | 807 | 0.210 |
Why?
|
| Spinal Cord Compression | 2 | 2021 | 21 | 0.200 |
Why?
|
| Subcutaneous Fat | 2 | 2013 | 17 | 0.200 |
Why?
|
| Robotics | 1 | 2023 | 43 | 0.190 |
Why?
|
| Fistula | 2 | 2020 | 17 | 0.190 |
Why?
|
| Cerebellar Neoplasms | 2 | 2013 | 30 | 0.190 |
Why?
|
| Radiculopathy | 3 | 2016 | 10 | 0.180 |
Why?
|
| Surgical Flaps | 1 | 2022 | 24 | 0.180 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 465 | 0.180 |
Why?
|
| Disability Evaluation | 3 | 2018 | 54 | 0.180 |
Why?
|
| Body Mass Index | 3 | 2019 | 405 | 0.180 |
Why?
|
| Pain Management | 1 | 2022 | 62 | 0.180 |
Why?
|
| Health Services | 1 | 2021 | 12 | 0.180 |
Why?
|
| Health Plan Implementation | 1 | 2021 | 9 | 0.180 |
Why?
|
| Incidence | 6 | 2020 | 568 | 0.170 |
Why?
|
| Health Status | 2 | 2021 | 148 | 0.170 |
Why?
|
| Malpractice | 1 | 2020 | 7 | 0.170 |
Why?
|
| Bone Screws | 2 | 2021 | 43 | 0.170 |
Why?
|
| Program Development | 1 | 2021 | 85 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2022 | 164 | 0.170 |
Why?
|
| Trauma Centers | 1 | 2021 | 123 | 0.160 |
Why?
|
| Movement Disorders | 1 | 2020 | 4 | 0.160 |
Why?
|
| Aneurysm, Ruptured | 1 | 2020 | 17 | 0.160 |
Why?
|
| Aneurysm | 1 | 2020 | 25 | 0.160 |
Why?
|
| Surgeons | 1 | 2020 | 50 | 0.160 |
Why?
|
| Propensity Score | 1 | 2020 | 59 | 0.160 |
Why?
|
| Spondylolisthesis | 2 | 2016 | 12 | 0.160 |
Why?
|
| Arteries | 1 | 2020 | 66 | 0.160 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 76 | 0.160 |
Why?
|
| Quality Improvement | 1 | 2020 | 123 | 0.160 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2019 | 10 | 0.150 |
Why?
|
| Blood Loss, Surgical | 2 | 2016 | 53 | 0.150 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 71 | 0.150 |
Why?
|
| Bone Transplantation | 1 | 2019 | 24 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 46 | 0.150 |
Why?
|
| Dyslipidemias | 1 | 2019 | 32 | 0.150 |
Why?
|
| X-Ray Film | 1 | 2018 | 10 | 0.150 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 215 | 0.150 |
Why?
|
| Heart Diseases | 1 | 2019 | 71 | 0.150 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2019 | 58 | 0.140 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 130 | 0.140 |
Why?
|
| Crime Victims | 1 | 2018 | 18 | 0.140 |
Why?
|
| Biomechanical Phenomena | 2 | 2020 | 182 | 0.140 |
Why?
|
| Bone Wires | 1 | 2017 | 3 | 0.140 |
Why?
|
| Early Ambulation | 1 | 2017 | 3 | 0.140 |
Why?
|
| Combined Modality Therapy | 3 | 2015 | 302 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2018 | 68 | 0.140 |
Why?
|
| Critical Care | 1 | 2018 | 49 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2018 | 66 | 0.140 |
Why?
|
| Powders | 1 | 2017 | 19 | 0.140 |
Why?
|
| T-Lymphocytes | 3 | 2008 | 285 | 0.130 |
Why?
|
| Deglutition Disorders | 1 | 2017 | 24 | 0.130 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2017 | 14 | 0.130 |
Why?
|
| Glioma | 3 | 2008 | 121 | 0.130 |
Why?
|
| Cognitive Dysfunction | 2 | 2017 | 265 | 0.130 |
Why?
|
| Hemoglobins | 1 | 2018 | 118 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 98 | 0.130 |
Why?
|
| Equipment Failure | 1 | 2016 | 31 | 0.130 |
Why?
|
| Quality of Health Care | 1 | 2017 | 83 | 0.130 |
Why?
|
| Intensive Care Units | 1 | 2016 | 50 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2017 | 63 | 0.130 |
Why?
|
| Sex Characteristics | 1 | 2017 | 172 | 0.130 |
Why?
|
| Hypertension | 1 | 2019 | 309 | 0.120 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2016 | 14 | 0.120 |
Why?
|
| Steroids | 1 | 2016 | 58 | 0.120 |
Why?
|
| Electroencephalography | 1 | 2017 | 140 | 0.120 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 18 | 0.120 |
Why?
|
| Anxiety | 1 | 2016 | 157 | 0.110 |
Why?
|
| Sex Factors | 1 | 2016 | 467 | 0.110 |
Why?
|
| CD24 Antigen | 1 | 2014 | 1 | 0.110 |
Why?
|
| Fetal Proteins | 1 | 2014 | 3 | 0.110 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 98 | 0.110 |
Why?
|
| Keratins | 1 | 2014 | 10 | 0.110 |
Why?
|
| T-Box Domain Proteins | 1 | 2014 | 9 | 0.110 |
Why?
|
| Cognition | 1 | 2017 | 327 | 0.110 |
Why?
|
| Biomarkers | 1 | 2018 | 770 | 0.110 |
Why?
|
| NF-kappa B | 1 | 2015 | 191 | 0.110 |
Why?
|
| Heterografts | 1 | 2014 | 66 | 0.110 |
Why?
|
| Bone Plates | 1 | 2014 | 18 | 0.110 |
Why?
|
| North Carolina | 4 | 2016 | 17 | 0.110 |
Why?
|
| Demography | 1 | 2014 | 93 | 0.100 |
Why?
|
| Drainage | 2 | 2013 | 45 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 314 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 270 | 0.100 |
Why?
|
| Brain Stem Neoplasms | 1 | 2013 | 12 | 0.100 |
Why?
|
| Supratentorial Neoplasms | 1 | 2013 | 4 | 0.100 |
Why?
|
| Anthropometry | 2 | 2012 | 93 | 0.100 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2013 | 33 | 0.100 |
Why?
|
| Hemangioma, Cavernous | 1 | 2013 | 3 | 0.100 |
Why?
|
| Tracheostomy | 1 | 2013 | 7 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2014 | 291 | 0.100 |
Why?
|
| Neurologic Examination | 2 | 2012 | 22 | 0.100 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 351 | 0.100 |
Why?
|
| Sarcoma | 1 | 2013 | 29 | 0.100 |
Why?
|
| Meningocele | 1 | 2012 | 5 | 0.100 |
Why?
|
| Cytokines | 1 | 2015 | 448 | 0.100 |
Why?
|
| Hernia | 1 | 2012 | 9 | 0.100 |
Why?
|
| Somatotypes | 1 | 2012 | 1 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 78 | 0.100 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2012 | 4 | 0.090 |
Why?
|
| Catecholamines | 1 | 2012 | 18 | 0.090 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 1338 | 0.090 |
Why?
|
| Postural Balance | 1 | 2012 | 41 | 0.090 |
Why?
|
| Ossification, Heterotopic | 1 | 2011 | 7 | 0.090 |
Why?
|
| Cerebellopontine Angle | 1 | 2011 | 8 | 0.090 |
Why?
|
| Body Weight | 1 | 2012 | 250 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 994 | 0.090 |
Why?
|
| Radiotherapy | 1 | 2011 | 41 | 0.090 |
Why?
|
| Disease Progression | 1 | 2012 | 475 | 0.080 |
Why?
|
| Manubrium | 1 | 2009 | 1 | 0.080 |
Why?
|
| Intervertebral Disc | 1 | 2009 | 5 | 0.080 |
Why?
|
| Sternum | 1 | 2009 | 7 | 0.080 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2009 | 10 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2021 | 265 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2008 | 97 | 0.080 |
Why?
|
| Mice | 3 | 2015 | 4732 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2008 | 111 | 0.080 |
Why?
|
| Clinical Protocols | 2 | 2021 | 46 | 0.080 |
Why?
|
| Registries | 3 | 2017 | 393 | 0.080 |
Why?
|
| Inpatients | 2 | 2021 | 60 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 66 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 1494 | 0.070 |
Why?
|
| Schools | 2 | 2020 | 83 | 0.070 |
Why?
|
| Myelography | 2 | 2020 | 8 | 0.070 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2008 | 6 | 0.070 |
Why?
|
| Visual Acuity | 1 | 2009 | 119 | 0.070 |
Why?
|
| Hospitalization | 2 | 2021 | 199 | 0.070 |
Why?
|
| Antigens | 1 | 2008 | 68 | 0.070 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2008 | 22 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 253 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 414 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2016 | 732 | 0.070 |
Why?
|
| Transfection | 1 | 2008 | 319 | 0.070 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2006 | 10 | 0.070 |
Why?
|
| Epidural Space | 1 | 2007 | 11 | 0.070 |
Why?
|
| Leukocyte Common Antigens | 1 | 2006 | 17 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 1 | 2006 | 35 | 0.060 |
Why?
|
| Immunity | 1 | 2006 | 26 | 0.060 |
Why?
|
| Neural Tube Defects | 1 | 2007 | 20 | 0.060 |
Why?
|
| Health Care Costs | 2 | 2020 | 50 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 194 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2008 | 667 | 0.060 |
Why?
|
| Craniotomy | 1 | 2006 | 61 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 378 | 0.060 |
Why?
|
| Animals | 3 | 2015 | 10580 | 0.060 |
Why?
|
| Gene Expression | 1 | 2006 | 417 | 0.060 |
Why?
|
| Karnofsky Performance Status | 2 | 2015 | 15 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 145 | 0.060 |
Why?
|
| Neoplasms | 1 | 2013 | 857 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 426 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2007 | 899 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2016 | 622 | 0.050 |
Why?
|
| Muscles | 1 | 2022 | 73 | 0.050 |
Why?
|
| Ilium | 1 | 2021 | 7 | 0.040 |
Why?
|
| Bone Matrix | 1 | 2021 | 4 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 11 | 0.040 |
Why?
|
| Patient Admission | 1 | 2021 | 29 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 14 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2015 | 278 | 0.040 |
Why?
|
| Gender Identity | 1 | 2020 | 25 | 0.040 |
Why?
|
| Hematocrit | 1 | 2020 | 26 | 0.040 |
Why?
|
| Neurosurgeons | 1 | 2020 | 22 | 0.040 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2020 | 11 | 0.040 |
Why?
|
| Policy | 1 | 2020 | 13 | 0.040 |
Why?
|
| Angiography | 1 | 2020 | 35 | 0.040 |
Why?
|
| Polyvinyls | 1 | 2020 | 14 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 164 | 0.040 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 48 | 0.040 |
Why?
|
| Peptides | 2 | 2015 | 293 | 0.040 |
Why?
|
| Pelvis | 1 | 2019 | 38 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 2020 | 47 | 0.040 |
Why?
|
| Parents | 1 | 2020 | 131 | 0.040 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2018 | 5 | 0.040 |
Why?
|
| Case Management | 1 | 2018 | 11 | 0.040 |
Why?
|
| Geriatrics | 1 | 2018 | 47 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 72 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2018 | 391 | 0.030 |
Why?
|
| Mental Health | 1 | 2018 | 110 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2017 | 91 | 0.030 |
Why?
|
| Illinois | 1 | 2016 | 3 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 82 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 988 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2016 | 79 | 0.030 |
Why?
|
| Students | 1 | 2018 | 199 | 0.030 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2016 | 8 | 0.030 |
Why?
|
| Veins | 1 | 2016 | 19 | 0.030 |
Why?
|
| Back Pain | 1 | 2016 | 21 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2015 | 15 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 21 | 0.030 |
Why?
|
| Camptothecin | 1 | 2015 | 16 | 0.030 |
Why?
|
| Pneumonia | 1 | 2016 | 89 | 0.030 |
Why?
|
| Chemokine CXCL1 | 1 | 2015 | 7 | 0.030 |
Why?
|
| Hyperalgesia | 1 | 2015 | 16 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2015 | 36 | 0.030 |
Why?
|
| Emergency Treatment | 1 | 2015 | 26 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 54 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2015 | 50 | 0.030 |
Why?
|
| Physical Stimulation | 1 | 2015 | 72 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2015 | 106 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 288 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2015 | 108 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2015 | 87 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2006 | 453 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2015 | 89 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 194 | 0.030 |
Why?
|
| Pons | 1 | 2013 | 7 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2013 | 21 | 0.030 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2013 | 4 | 0.030 |
Why?
|
| Neuralgia | 1 | 2013 | 19 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2013 | 100 | 0.020 |
Why?
|
| Awards and Prizes | 1 | 2012 | 9 | 0.020 |
Why?
|
| Herniorrhaphy | 1 | 2012 | 17 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2013 | 131 | 0.020 |
Why?
|
| Health Surveys | 1 | 2012 | 84 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 114 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 431 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 74 | 0.020 |
Why?
|
| Electrodes | 1 | 2012 | 72 | 0.020 |
Why?
|
| Universities | 1 | 2012 | 124 | 0.020 |
Why?
|
| Neurosurgery | 1 | 2012 | 76 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 87 | 0.020 |
Why?
|
| Mutation | 1 | 2013 | 864 | 0.020 |
Why?
|
| Viral Matrix Proteins | 1 | 2008 | 6 | 0.020 |
Why?
|
| Electroporation | 1 | 2008 | 8 | 0.020 |
Why?
|
| Indians, North American | 1 | 2013 | 534 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 101 | 0.020 |
Why?
|
| Chemokines | 1 | 2008 | 74 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2008 | 120 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2008 | 210 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2006 | 6 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2006 | 28 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2006 | 51 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2006 | 90 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2006 | 61 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2008 | 142 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2006 | 126 | 0.020 |
Why?
|
| Cell Movement | 1 | 2008 | 373 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 194 | 0.020 |
Why?
|
| Astrocytes | 1 | 2006 | 79 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2008 | 1009 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 465 | 0.010 |
Why?
|